Analystreport

ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Chardan Capital from $2.00 to $2.50. They now have a "buy" rating on the stock.

ProQR Therapeutics N.V. - Ordinary Shares  (PRQR) 
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: proqr.com